A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

111

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

August 31, 2025

Conditions

Locally Advanced Solid TumorMetastatic TumorColorectal Adenocarcinoma

Interventions

DRUG

TST003

IV humanized anti-GREM1 monoclonal antibody

Trial Locations (3)

Mary Crowley, Dallas

NEXT Oncology, San Antonio

OHSU, Portland

All Listed Sponsors

lead

Suzhou Transcenta Therapeutics Co., Ltd.

INDUSTRY